

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67287-05
Application Number	Unknown
Filing Date	Herewith
First Named Inventor	Ira H. Pastan
Art Unit	Unknown
Examiner Name	Unknown

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
DB		5,608,039	March 4, 1997	Pastan et al.
DB		2003/0103963	June 5, 2003	Cheung

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
DB		Modak, S., et al., "Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. <i>Cancer Research</i> , 15 May 2001, Vol. 61, pages 4048-4054.
DB		Juhl H. et al., "Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. <i>Immunobiology</i> , 1997, Vol. 197, pages 444-459.

EXAMINER SIGNATURE: /David Blanchard/

DATE CONSIDERED: 02/07/2007


* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>		Attorney Docket Number	4239-67287-05		
		Application Number	10/537,061		
		Filing Date	June 1, 2005		
		First Named Inventor	Pastan		
		Art Unit	1653		
		Examiner Name	Not yet assigned		
U.S. PATENT DOCUMENTS					
Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.					
Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee	
DB		2002/0102264	1 Aug 2002	Cheung	
FOREIGN PATENT DOCUMENTS					
Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
DB		WIPO/PCT	WO 02/32375	25 April 2002	Cheung
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			
DB		CHEUNG <i>et al.</i> , "Anti-Idiotypic Antibody as the Surrogate Antigen for Cloning acFv and its Fusion Proteins," <i>Hybridoma and Hybridomics</i> , 21(6):433-443, 2002			
		CHEUNG <i>et al.</i> , "Anti-Idotypic Antibody Facilitates scFv Chimeric Immune Receptor Gene Transduction and Clonal Expansion of Human Lymphocytes for Tumor Therapy," <i>Hybridoma and Hybridomics</i> , 22(4):209-218, 2003			
		MODAK <i>et al.</i> , "Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor," <i>Med. Pediatr. Oncol.</i> 39:547-551, 2002			
		MODAK <i>et al.</i> , "Radioimmunotargeting of Human Rhabdomyosarcoma Using Monoclonal Antibody 8H9," <i>Cancer Radiother Biopharm</i> 20(5):534-546, 2005			
DB		ONDA <i>et al.</i> , "In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma," <i>Cancer Research</i> 64:1419-1424, 2004			

EXAMINER SIGNATURE: /David Blanchard/

DATE CONSIDERED: 02/07/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-67287-05
	Application Number	10/537,061
	Filing Date	June 1, 2005
	First Named Inventor	Pastan
	Art Unit	1653
Examiner Name		Not yet assigned.

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
DB		PCT	WO 02/32375	24 Apr 2002	Cheung
DB		PCT	WO 03/075846	18 Sept 2003	Cheung
DB		Japan	2002-253262	10 Sept 2002	Sugimoto

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
DB		Barth, "Technology evaluation: BL22, NCI," <i>Current Opinion in Molecular Therapeutics</i> 4(1):72-75 (2002)
↓		Cheung et al., "Anti-Idiotypic as the Surrogate Antigen for Cloning scFv and its Fusion Proteins," <i>Hybridoma and Hybridomics</i> 21(6):433-443 (2002)
↓		Kreitman, et al., "Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia," <i>N. Engl. J. Medicine</i> 345(4):241-247 (July 26, 2001)
↓		Kreitman, "Toxin-Labeled Monoclonal Antibodies," <i>Current Pharmaceutical Biotechnology</i> 2:313-325 (2001)
↓		Modak, et al., "Disialoganglioside GD ₂ and antigen 8H9: Potential targets for antibody-based immunotherapy against desmoplastic small round cell tumor (DSRCT) and rhabdomyosarcoma (RMS)," <i>Proceedings of the American Association for Cancer Research</i> 40:474 (March 1999) <i>Abstract only</i>
↓		Onda, et al., "Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity," <i>Cancer Research</i> 61:5070-5077 (July 1, 2001).

EXAMINER
SIGNATURE: /David Blanchard/

DATE
CONSIDERED: 02/07/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number	4239-67287-05
Application Number	10/537,061
Filing Date	June 1, 2005
First Named Inventor	Pastan
Art Unit	1653
Examiner Name	

EXAMINER SIGNATURE: /David Blanchard/	DATE CONSIDERED: 02/07/2007
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	